MetaCap

Autolus Therapeutics (AUTL) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics (AUTL) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 26.2% versus a loss of 67.3%. Lexeo Therapeutics is the larger company by market cap ($245.1 million vs $241.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-26.24%LXEO-67.33%
+115%+18%-80%
Nov 21, 20251 yearNov 20, 2026
AUTL-77.82%LXEO-70.55%
+84%-2%-88%
Oct 30, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus LXEO key metrics
MetricAUTLLXEO
Share price$0.9073$2.96
Market cap$241.65M$245.05M
1-day change-7.38%+0.34%
YTD return-54.41%-70.19%
1-year return-26.24%-67.33%
5-year return-85.51%—
EPS (TTM)$-0.96$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M—
Revenue growth (YoY)+644.94%—
Net income (latest FY)$-287.53M$-100.00M
Gross margin-27.83%—
Operating margin-358.87%—
Net margin-381.40%—
52-week high$2.58$10.99
52-week low$0.896$2.55
Distance from 52-week high-64.83%-73.07%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+821.42%+748.31%
Average volume2.07M1.98M
Shares outstanding266.34M82.79M
Employees75268
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AUTL has outperformed LXEO by 41.1 percentage points over the past year.

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

AUTL vs LXEO FAQ

Which is bigger, Autolus Therapeutics or Lexeo Therapeutics?

Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $245.05M compared with $241.65M for Autolus Therapeutics (AUTL).

Which stock has performed better over the past year, AUTL or LXEO?

AUTL returned -26.24% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.

Are Autolus Therapeutics and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons